DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant…Original Article
You may also like
UroGen Submits Completed UGN-102 NDA Seeking Approval...
FDA Accepts LEO Pharma’s Filing of Delgocitinib...
AbbVie Submits Biologics License Application to the...
PTC Therapeutics Announces FDA Acceptance for Filing...
Stealth BioTherapeutics Announces Positive Vote from...
U.S. Food and Drug Administration (FDA) Accepts New...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.